$NUVL received 22 mentions over a 12-month period from June 2025 through June 2026 across four distinct FinTwit voices, with @jacobplieth accounting for 24 mentions as the most-active commentator on the biotech stock. The conversation centered on corporate activity, with the most recent discussion noting that GSK completed an acquisition of Nuvalent. The stock appeared in premarket movement tracking alongside other biotech names, with $NUVL mentioned as one of two names with real catalysts driving significant intraday movement.